Login to Your Account



Other News To Note


Thursday, June 21, 2012
• InterMune Inc., of Brisbane, Calif., completed its sale of rights to Actimmune (interferon gamma-1b) to Vidara Therapeutics International Ltd., of Dublin, Ireland, for $55 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription